Drug data last refreshed 15h ago · AI intelligence enriched 1w ago
CEFOBID (cefoperazone sodium) is a third-generation cephalosporin antibiotic administered by injection for treatment of serious bacterial infections. It works by inhibiting bacterial cell wall synthesis and is indicated for a broad spectrum of gram-positive and gram-negative infections. The drug is used across multiple therapeutic areas including respiratory, urinary, gynecological, and intra-abdominal infections.
As a mature, pre-LOE product with moderate competitive pressure (30%), the brand team is likely focused on defensive strategies and maintaining market position rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on CEFOBID offers exposure to mature product management, competitive defense strategies, and hospital/acute care market dynamics. This is an excellent platform to develop market access expertise, managed care negotiations, and cost-containment communication skills in a defensive commercial environment.
Worked on CEFOBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.